278 related articles for article (PubMed ID: 35484264)
1. Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA.
Chandran SS; Ma J; Klatt MG; Dündar F; Bandlamudi C; Razavi P; Wen HY; Weigelt B; Zumbo P; Fu SN; Banks LB; Yi F; Vercher E; Etxeberria I; Bestman WD; Da Cruz Paula A; Aricescu IS; Drilon A; Betel D; Scheinberg DA; Baker BM; Klebanoff CA
Nat Med; 2022 May; 28(5):946-957. PubMed ID: 35484264
[TBL] [Abstract][Full Text] [Related]
2. Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations.
Shen M; Chen S; Han X; Hao Y; Wang J; Li L; Chen T; Wang B; Zou L; Zhang T; Zhang W; Han X; Wang W; Yu H; Li K; Liu S; Jin A
Cancer Immunol Immunother; 2024 Jun; 73(8):150. PubMed ID: 38832948
[TBL] [Abstract][Full Text] [Related]
3. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics.
Ade CM; Sporn MJ; Das S; Yu Z; Hanada KI; Qi YA; Maity T; Zhang X; Guha U; Andresson T; Yang JC
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37758652
[TBL] [Abstract][Full Text] [Related]
4. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
5. Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing.
Shafer P; Leung WK; Woods M; Choi JM; Rodriguez-Plata CM; Maknojia A; Mosquera A; Somes LK; Joubert J; Manliguez A; Ranjan R; Burt B; Lee HS; Zhang B; Fuqua S; Rooney C; Leen AM; Hoyos V
Cytotherapy; 2024 Mar; 26(3):266-275. PubMed ID: 38231165
[TBL] [Abstract][Full Text] [Related]
6. Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen.
Chen P; Chen D; Bu D; Gao J; Qin W; Deng K; Ren L; She S; Xu W; Yang Y; Xie X; Liao W; Chen H
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37076248
[TBL] [Abstract][Full Text] [Related]
7. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D.
Sim MJW; Lu J; Spencer M; Hopkins F; Tran E; Rosenberg SA; Long EO; Sun PD
Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12826-12835. PubMed ID: 32461371
[TBL] [Abstract][Full Text] [Related]
8. Discovery of U2AF1 neoantigens in myeloid neoplasms.
Biernacki MA; Lok J; Black RG; Foster KA; Cummings C; Woodward KB; Monahan T; Oehler VG; Stirewalt DL; Wu D; Rongvaux A; Deeg HJ; Bleakley M
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38164756
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for T cell recognition of cancer neoantigens and implications for predicting neoepitope immunogenicity.
Mariuzza RA; Wu D; Pierce BG
Front Immunol; 2023; 14():1303304. PubMed ID: 38045695
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for self-discrimination by neoantigen-specific TCRs.
Finnigan JP; Newman JH; Patskovsky Y; Patskovska L; Ishizuka AS; Lynn GM; Seder RA; Krogsgaard M; Bhardwaj N
Nat Commun; 2024 Mar; 15(1):2140. PubMed ID: 38459027
[TBL] [Abstract][Full Text] [Related]
11. Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
Plewa N; Poncette L; Blankenstein T
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822673
[TBL] [Abstract][Full Text] [Related]
12. T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T.
Erickson TA; Shih YP; Fass J; Jang M; Tran E
Thyroid; 2022 Jul; 32(7):789-798. PubMed ID: 35587601
[No Abstract] [Full Text] [Related]
13. Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expression.
Nguyen KB; Roerden M; Copeland CJ; Backlund CM; Klop-Packel NG; Remba T; Kim B; Singh NK; Birnbaum ME; Irvine DJ; Spranger S
Elife; 2023 Aug; 12():. PubMed ID: 37548358
[TBL] [Abstract][Full Text] [Related]
14. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
[TBL] [Abstract][Full Text] [Related]
15. Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer.
Aparicio B; Repáraz D; Ruiz M; Llopiz D; Silva L; Vercher E; Theunissen P; Tamayo I; Smerdou C; Igea A; Santisteban M; Gónzalez-Deza C; Lasarte JJ; Hervás-Stubbs S; Sarobe P
Front Immunol; 2022; 13():985886. PubMed ID: 36405725
[TBL] [Abstract][Full Text] [Related]
16. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
17. Structural Basis for Self-Discrimination by Neoantigen-Specific TCRs.
Finnigan JP; Newman JH; Patskovsky Y; Patskovska L; Ishizuka AS; Lynn GM; Seder RA; Krogsgaard M; Bhardwaj N
Res Sq; 2023 Jan; ():. PubMed ID: 36778273
[TBL] [Abstract][Full Text] [Related]
18. Emerging Strategies in TCR-Engineered T Cells.
Wei F; Cheng XX; Xue JZ; Xue SA
Front Immunol; 2022; 13():850358. PubMed ID: 35432319
[TBL] [Abstract][Full Text] [Related]
19. Characterization of CD8
Shinkawa T; Tokita S; Nakatsugawa M; Kikuchi Y; Kanaseki T; Torigoe T
Oncoimmunology; 2021 Jan; 10(1):1870062. PubMed ID: 33537174
[TBL] [Abstract][Full Text] [Related]
20. Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers.
Li Q; Hu W; Liao B; Song C; Li L
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]